Today marked a significant milestone in healthcare as the World Health Organization (WHO) unveiled the Patient Safety Rights Charter during the Global Ministerial Summit on Patient Safety. This groundbreaking Charter, the first of its kind, delineates patients’ rights within the…
Merck’s Curiosity Cube Hits the Road: Inspiring 45,000 Students Across 14 Countries Merck, a global leader in science and technology, has launched its 2024 Curiosity Cube tour from Darmstadt, Germany, marking the beginning of a journey to engage and educate…
Modalis Therapeutics Corporation (Modalis) (Tokyo Stock Exchange: 4883) announced that it has entered into an agreement with Ginkgo Bioworks (Ginkgo) to join the Ginkgo Technology Network. This strategic alliance will enable Ginkgo’s global customers in the cell and gene therapy fields…
Shionogi B.V., the European arm of Shionogi & Co., Ltd., has revealed that the European Commission has granted Orphan Medicinal Product designation to zatolmilast (BPN14770), an investigational treatment for Fragile X syndrome (FXS), a prominent cause of inherited intellectual disability…
AbbVie (NYSE: ABBV) has revealed interim findings from an ongoing Phase 3 extension study, spanning 156 weeks, investigating the sustained safety and tolerability of oral atogepant for migraine prevention in individuals with chronic or episodic migraine. The analysis indicates that…
In a recent announcement, the World Health Organization (WHO) has provided updates regarding the simultaneous treatment of drug-resistant tuberculosis (TB) and hepatitis C (HCV). The latest evidence suggests that administering treatment for HCV alongside multi-drug resistant or rifampicin-resistant TB (MDR/RR-TB)…
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has announced its plans to unveil the financial results for the first quarter of 2024 on Wednesday, May 8, 2024, at 7:00 a.m. ET through a press release. Subsequent to the release,…
ICON, a globally renowned healthcare intelligence and clinical research organization, has announced that its Chief Financial Officer, Brendan Brennan, will be stepping down from his position in the fourth quarter of this year to pursue an opportunity outside the CRO…
Updated findings on overall survival (OS) from a planned evaluation, encompassing around 75% of data, reveal an OS hazard ratio below 1.0 (HR<1.0) within the intent-to-treat (ITT) population, not adjusted for cross-over. Consistency is observed in radiographic progression-free survival (rPFS)…
Eisai Co., Ltd. (based in Tokyo, CEO: Haruo Naito) and Biogen Inc. (headquartered in Cambridge, Massachusetts, CEO: Christopher A. Viehbacher) have jointly announced the submission of a Supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA).…
Bristol Myers Squibb (NYSE: BMY) has announced the successful results of the pivotal Phase 3 KRYSTAL-12 study, which evaluated KRAZATI® (adagrasib) as a monotherapy for patients with previously treated locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring a…
Bristol Myers Squibb (NYSE: BMY) provided an update today following the preliminary analysis of findings from the first of two induction studies within the Phase 3 YELLOWSTONE clinical trial program, which assesses Zeposia (ozanimod) in adult patients dealing with moderate…